ArticlePLoS pathogens2011
Galactosaminogalactan, a new immunosuppressive polysaccharide of Aspergillus fumigatus.
Article in PLoS pathogens, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 232 citations in OpenAlex.
- Synthesis and Immunological Evaluation of Pel-Derived Glycoconjugate Vaccine Candidates againstJACS Au · 2026Article
- Comparative analysis towards the identification of genome wide characteristics of a beneficial fungal endophyte.Scientific reports · 2026Article
- Review
- Aspergillus fumigatus Cell Wall: Current Advances in Structural Elucidation Methods.Methods in molecular biology (Clifton, N.J.) · 2026Article
- The structural language of fungal cell wall sugars in WHO priority fungi: the determinant of pathogenicity and the gateway to new therapies.Frontiers in immunology · 2026Review
- Evaluating the Potential of Galactosaminogalactan as a Diagnostic Target for Invasive Aspergillosis.Mycoses · 2025Article
- Article
- TheJournal of fungi (Basel, Switzerland) · 2025Article
- Regulation of Necroptosis by Aspergillus fumigatus Exopolysaccharide in Human Macrophages Derived from THP-1 Cells: Involvement of the RIP1-RIP3-MLKL Signaling Axis.Current microbiology · 2025Article
- Potential Antioxidant and Neuroprotective Effect of Polysaccharide Isolated from DigüeñeJournal of fungi (Basel, Switzerland) · 2025Article
- Comparative analysis of polysaccharide and cell wall structure in Aspergillus nidulans and Aspergillus fumigatus by solid-state NMR.Carbohydrate polymers · 2025Article
- Platelets as central hubs of inflammation.Frontiers in immunology · 2025Review
- Human Gb3/CD77 synthase: a glycosyltransferase at the crossroads of immunohematology, toxicology, and cancer research.Cellular & molecular biology letters · 2024Review
- Comparative Analysis of the Aspergillus fumigatus Cell Wall Modification and Ensuing Human Dendritic Cell Responses by β-(1,3)-Glucan Synthase Inhibitors-Caspofungin and Enfumafungin.Mycopathologia · 2024Article
- Potential Bioactivities, Chemical Composition, and Conformation Studies of Exopolysaccharide-DerivedJournal of fungi (Basel, Switzerland) · 2024Article
- Synthesis and elucidation of strained galactopyronose esters as selective cyclooxygenase-2 inhibitor: a comprehensive computational approach.RSC advances · 2024Article
- Comparative Analysis of Polysaccharide and Cell Wall Structure inbioRxiv : the preprint server for biology · 2024Article
- Interplay between host humoral pattern recognition molecules controls undue immune responses against Aspergillus fumigatus.Nature communications · 2024Article
- Characterization of theMicroorganisms · 2024Article
- CD56-mediated activation of human natural killer cells is triggered by Aspergillus fumigatus galactosaminogalactan.PLoS pathogens · 2024Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new polysaccharide secreted by the human opportunistic fungal pathogen Aspergillus fumigatus has been characterized. Carbohydrate analysis using specific chemical degradations, mass spectrometry, ¹H and ¹³C nuclear magnetic resonance showed that this polysaccharide is a linear heterogeneous galactosaminogalactan composed of α1-4 linked galactose and α1-4 linked N-acetylgalactosamine residues where both monosacharides are randomly distributed and where the percentage of galactose per chain varied from 15 to 60%. This polysaccharide is antigenic and is recognized by a majority of the human population irrespectively of the occurrence of an Aspergillus infection. GalNAc oligosaccharides are an essential epitope of the galactosaminogalactan that explains the universal antibody reaction due to cross reactivity with other antigenic molecules containing GalNAc stretches such as the N-glycans of Campylobacter jejuni. The galactosaminogalactan has no protective effect during Aspergillus infections. Most importantly, the polysaccharide promotes fungal development in immunocompetent mice due to its immunosuppressive activity associated with disminished neutrophil infiltrates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.